MICHAEL SUNDSTRÖM TEAM
Michael Sundstrom received his PhD from Uppsala, followed by PostDoctoral studies at Karolinska Institute. From 1993-2000 he was at Pharmacia as Director for structure-based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). From end of 2011, he was VP Discovery Research at Karolinska Development. He then re-joined the SGC and Karolinska Institutet and is since mid-2014 as Scientific Director for the SGC at KI.
Michael has three main research responsibilities 1) member of the global research leadership team coordinating projects and activities of common interest within the consortium; 2) site head for SGC Karolinska and 3) main scientific focus and responsibility for the SGC Tissue Platforms at Karolinska, Oxford and Montreal; working to establish high quality cell-based assays using patient-derived cell systems in inflammation and neurodegenerative diseases. The research activities carried out at the laboratory are focused on translational assays and target validation in systemic auto-immune diseases and inflammatory bowel diseases, as well as the generation of high quality recombinant antibodies.
Arrowsmith CH et al. The promise and peril of chemical probes. Nature Chemical Biology. 2015 Aug;11(8):536-41.
Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M. Preclinical target validation using patient-derived cells. Nat Rev Drug Discov. 2015 Mar;14(3):149-50.
Knapp S and Sundström M. Recently targeted kinases and their inhibitors – the path to clinical trials. Curr Opin Pharmacol. 2014 Aug 8;17C:58-63.
Francavilla C, Rigbolt K, Emdal K, Vernet E, Bekker-Jensen D, Streicher W, Wikström M, Sundstrom M, Cavallaro U, Blagoev B, Olsen JV. Functional proteomics defines the molecular switch underlying FGFR2b trafficking and response. Molecular Cell. S1097-2765(13)00575-3.
Soundararajan M, Willard FS, Kimple AJ, Turnbull AP, Ball LJ, Schoch GA, Gileadi C, Fedorov OY, Dowler EF, Higman VA, Hutsell SQ, Sundström M, Doyle DA, Siderovski DP. Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6457-62.
Uhlén M, Graslund S, Sundstrom M. A pilot project to generate affinity reagents to human proteins. Nature Methods. 2008 5(10):854-5.
Fedorov O, Bullock A, Marsden B, Rellos P, Muller S, Schwaller J, Sundstrom M, Knapp S. Systematic Analysis of Ser/Thr Kinase Inhibitor Binding Profiles. Proc Natl Acad Sci U S A. 2007 Dec 18; 104(51):20523-8.
Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka E, Benoit M. Lienard R, Bray JE, Savitsky P, Gileadi von Delft F, Rose RR, Offer J, Scheinost JC, Borowski M, Sundstrom M, Schofield CJ, Oppermann U. Crystal structures of human histone H3K9 and H3K36 demethylase JMJD2A reveal the basis for substrate specificity. Nature. 2007 5;448(7149):87-91.